Previously known as Hana Biosciences, Inc. Talon Therapeutics, Inc. changed its name in December 2010. In July 2013, Talon was acquired by Spectrum Pharmaceuticals and ceased trading. Talon is a biopharmaceutical company focused on cancer care. Its lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate, which is in the development for the treatment of acute lymphoblastic leukemia and lymphomas. TIn addition to Marqibo® (vincCRIStine sulfate LIPOSOME injection) which received accelerated approval from the US FDA for the treatment of Philadelphia chromosome negative adult acute lymphoblastic leukemia (ALL) patients in second or greater relapse or whose disease has progressed following two or more prior lines of anti-leukemia therapy, Talon has additional pipeline opportunities some of which like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity. The company?s product candidates also include Menadione Topical Lotion, a supportive care product candidate for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, a type of anti-cancer agent used in the treatment of cell lung cancer, pancreatic, colorectal, breast, and head and neck cancer; and Brakiva (topotecan liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, including small cell lung cancer and ovarian cancer. In addition, its development stage product consists of Alocrest (vinorelbine liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, such as non-small-cell lung cancer. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. In addition to Marqibo® (vincCRIStine sulfate LIPOSOME injection) which received accelerated approval from the US FDA for the treatment of Philadelphia chromosome negative adult acute lymphoblastic leukemia (ALL) patients in second or greater relapse or whose disease has progressed following two or more prior lines of anti-leukemia therapy, Talon has additional pipeline opportunities some of which like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.
